CORCEPT THERAPEUTICS INC — Director's Dealing 2016

Nov 17, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2016-11-15

Reporting Person: ENRIGHT PATRICK G (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-15	Common Stock	S	154359	$9.5534	Disposed	14362573	Indirect
2016-11-15	Common Stock	S	3094	$9.5534	Disposed	191864	Indirect
2016-11-16	Common Stock	S	17052	$9.5087	Disposed	14345521	Indirect
2016-11-16	Common Stock	S	342	$9.5087	Disposed	191522	Indirect

Footnotes

F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected..

F2: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein.

F3: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein.

F4: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.